This site was built to comply to Web authoring standards, and is best viewed in a standards-compliant browser. You may download one free from Netscape or Microsoft. You do not need to download a new browser, however, to have complete access to all information in this site.

September 07, 2010 (updated 8/26/2010)

Home | Contact Us | Glossary | Site Map | Legal Notices

SearchGO

PRESS RELEASES

June 10, 2010

Harbor BioSciences Announces Closing of $2.06 Million Equity Financing >>

June 7, 2010

Harbor BioSciences Apoptone® for Prostate Cancer Shows Activity at All Doses Tested – Newest Phase I/IIa Data Presented at ASCO Annual Meeting >>

June 7, 2010

Harbor BioSciences Announces $2.06 Million Equity Financing >>

May 17, 2010

Harbor BioSciences Apoptone® Clinical Results Poster Selected for ASCO Annual Meeting >>

May 10, 2010

Triolex® Demonstrates Evidence of Anti-Inflammatory Activity in a Phase IIa Clinical Trial in a Subset of Type 2 Diabetes Mellitus Patients >>

View All Releases >>

HIGHLIGHTS

	8-K Entry into a Material Definitive Agreement
8-K Entry into a Material Definitive Agreement >>

	Triolex Clinical Development Backgrounder
Triolex® Clinical Development Backgrounder for Obesity-induced Insulin Resistance and Type-2 Diabetes Mellitus >>

	Harbor BioSciences 2010 Proxy
Harbor BioSciences 2010 Proxy Notice, Statement and Card >>

Company | Technology | Pipeline | Programs | News Room | Investors | Careers

Home | Contact Us | Glossary | Legal Notices